u/Icy-Let5120

Dr. Heidi Overton's explicit public stance or voting record regarding the Right to Try framework—which allows terminally ill patients access to experimental treatments outside clinical trials—is not extensively documented in dedicated policy papers. However, her positions and actions within government and conservative health policy circles provide a clear picture of her stance: 

1. Alignment with Executive Policy & Support for Expanded Access
   White House Domestic Policy Initiatives: As Deputy Director of the White House Domestic Policy Council, Dr. Overton supported the administration's push to expand access to unapproved treatments for desperately ill patients. 
   Right to Try Directives: During executive order announcements regarding accelerated medical research (such as opening expanded pathways for investigational drugs like ibogaine and breakthrough psychedelics under Right to Try provisions for severe mental health conditions and traumatic brain injuries), Dr. Overton worked directly on implementing these initiatives to remove bureaucratic FDA hurdles. 
2. General Regulatory Philosophy
   America First Policy Institute (AFPI): Prior to her White House role, Dr. Overton served as Vice Chair of the Center for a Healthy America and Chief Policy Officer at AFPI. Her work emphasized healthcare transparency, patient empowerment, reduced administrative burden, and deregulation—core tenets aligned with the Right to Try movement. 
   Biopharma & Market Stance: Analysts assessing her potential impact as FDA Commissioner note that while her public trail on specific accelerated approval pathways is limited, her approach aligns with administrative goals of modernizing FDA oversight, facilitating faster access to therapies, and balancing innovation with institutional stability. 
   In short, while Dr. Overton has focused much of her public health policy work on price transparency, preventive medicine, and administrative efficiency, her policy portfolio in the White House directly supports using the Right to Try framework and accelerated FDA pathways to broaden patient access to investigational therapies.